2015 ASCO Annual Meeting

Physicians, scientists, and allied health staff from Mayo Clinic and Mayo Medical Laboratories will be delivering numerous presentations and abstracts at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Mayo Medical Laboratories representatives will also be available at booth #5111 in the exhibit hall to discuss:

  • COLON CANCERS: Targeted (BRAF, NRAS, KRAS and HRAS) next-generation sequencing testing to evaluate somatic mutations, assess prognosis and guide treatment
  • SOLID TUMOR CANCERS: 50-gene next generation sequencing panel helps tailor therapies to the individual patient
  • NON-SMALL CELL LUNG CARCINOMAS: EGFR mutation analysis with ALK FISH reflex helps to guide therapy
  • HEMATOLOGY: Comprehensive testing approaches to diagnose and treat the full spectrum of hematologic disorders
  • PATHOLOGY CONSULTATION SERVICE: Access to 90+ pathologists with subspecialty expertise in all areas of pathology


The new RAS/RAF Targeted Gene Panel by Next Generation Sequencing, Tumor, test is now available. Using next-generation sequencing testing to evaluate somatic mutations within the BRAF, NRAS, KRAS and HRAS genes, this test can assess prognosis and guide treatment of patients with colorectal cancer.



This gene panel cancer test helps tailor therapies to the individual patient based on the unique genomic signature of the patient’s tumor. This test scans specific regions in 50 genes known to affect tumor growth and response to therapies. The test is now available to Mayo Clinic patients and to providers worldwide through Mayo Medical Laboratories.



Targeted inhibitors have proven to be remarkably successful against epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) in patients with certain EGFR mutations and ALK rearrangements, and this has opened a new era of targeted therapy in advanced NSCLC.



As hematology and hematopathology has become an increasingly complex subspecialty, particularly with neoplastic disorders of blood and bone marrow, providing diagnostic, prognostic, and treatment information now requires going beyond the standard test offerings of other laboratories.

Our comprehensive test menu has been created to diagnose and treat the full spectrum of hematologic disorders.



Mayo Clinic Rochester is staffed by pathologists whose expertise and special interests cover the entirety of pathology–from surgical pathology with all of its respective subspecialty areas, to Hematopathology, Renal Pathology, and Dermatopathology.

A large number of our consultative cases are reviewed by more than one subspecialist pathologist to ensure the best interpretation. This close relationship among Mayo Clinic’s pathologists, clinical laboratorians, and oncologists creates clinical and research collaboration and generates the unique ability to successfully integrate state-of-the-art scientific achievements into clinical practice for patients.

This collaboration also ensures that the right tests are developed, validated, and implemented for the clinical practice and that these tests are ordered at the right time and in the right clinical scenario to help guide patient care.

When a difficult case poses several differential diagnoses, access to the expertise of Mayo Clinic’s consultant working groups creates, in essence, an ad hoc consensus conference or tumor board to form the best opinion.



A complete list of Mayo Clinic presentations and abstracts can be found here (search "Mayo").

Pathology Challenges in Limited Resource Settings
Presenter: Matthew Zarka, M.D.
Session: Global Oncology Symposium
Type: Special Session
Date: Friday, May 29, 2015
Time: 4:50 – 5:10 p.m.
Location: S100a

Melanoma/Skin Cancers
Presenter: Svetomir Markovic, MD, PhD
Session: Highlights of the Day Session
Date: Sunday, May 31, 2015
Time: 8:45 – 9:00 a.m.
Location: E Hall D1

Melanoma/Skin Cancers
Presenter: Svetomir Markovic, M.D., Ph.D.
Session:  Scientific Special Session
Date: Sunday, May 31, 2015
Time: 4:00 – 4:20 p.m.
Location: S100bc

Medical Management of Low-Grade Glioma
Presenter: Jan Buckner, M.D.
Session:  Meet the Professor Session
Date: Monday, June 1, 2015
Time: 10:05 – 10:25 a.m.
Location: E451b

A complete list of Mayo Clinic presentations and abstracts can be found here (search "Mayo").


Brent Westra

Brent Westra is a Marketing Segment Manager at Mayo Medical Laboratories. He leads marketing strategies for product management and specialty testing along with new media innovations. Brent has worked at Mayo Clinic since 2011.